Efficacy and Safety of Torcetrapib, a Novel Cholesteryl Ester Transfer Protein Inhibitor, in Individuals With Below-Average High-Density LipoproteinCholesterolLevelsonaBackgroundofAtorvastatin

This publication has 12 references indexed in Scilit:

• Effectiveness of Inhibition of Cholesteryl Ester Transfer Protein by JTT-705 in Combination With Pravastatin in Type II Dyslipidemia
  The American Journal of Cardiology, 2005
• Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease
  New England Journal of Medicine, 2005
• Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2
  Circulation, 2004
• Inhibition of cholesteryl ester transfer protein activity: A new therapeutic approach to raising high-density lipoprotein
  Current Atherosclerosis Reports, 2004
• Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
  New England Journal of Medicine, 2004
• Effect of Intensive Compared With Moderate Lipid-Lowering Therapy on Progression of Coronary Atherosclerosis
  JAMA, 2004
• European guidelines on cardiovascular disease prevention in clinical practice Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts)
  European Heart Journal, 2003
• Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
  JAMA, 2001
• Current Perspectives on Statins
  Circulation, 2000
• Dose response studies II. analysis and interpretation
  Journal of Biopharmaceutical Statistics, 1995